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Background: The effect of preinjury beta blockade on heart rate during initial trauma resuscitation is
unclear. We hypothesized that preinjury beta blockade does not affect the heart rate response to initial
trauma resuscitation.
Methods: A case-control study of patients admitted to a level I trauma center was conducted. Medical
records were reviewed for demographics, medications, injury information, and hemodynamic proﬁles.
Logistic regression identiﬁed correlations between preinjury beta blockade and hemodynamics during
initial trauma resuscitation and in-hospital mortality.
Results: There were 76 deaths (cases) and 304 survivors (controls). Mean pre-resuscitation heart rate was
83 in patients on beta blocker and 89 in patients not on beta blocker (p ¼ 0.007). Mean post-resuscitation
heart rate was 80 in patients on beta blocker and 85 in patients not on beta blocker (p ¼ 0.02). Tachy-
cardia was present in 14.3% with preinjury beta blocker and 29.7% without (p ¼ 0.009). Bradycardia was
present in 7.1% with preinjury beta blocker and 2.3% without (p ¼ 0.035). Of all patients who presented
with an abnormal heart rate, 46% of patients on beta blocker attained a normal heart rate after resus-
citation vs. 53% of patients not on beta blocker (p ¼ not signiﬁcant).
Conclusion: Preinjury beta blockade is associated with a slower presenting heart rate, more bradycardia,
less tachycardia, but no difference in mortality or ability to achieve a normal heart rate with
resuscitation.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Elderly trauma patients represent a unique challenge due to
higher levels of comorbidity and higher mortality.1e3 Elderly
patients account for 28% of trauma-related deaths in the United
States.4 The use of beta blockingmedications is increasing in elderly
patients with cardiovascular diseasewith approximately 7.5million
Americans currently taking beta-blockers regularly for hyperten-
sion.5e7
Perioperative beta blocker use has been shown to reduce
morbidity and mortality in selected patients undergoing elective
noncardiac surgery.8,9 Outcomes of trauma patients taking beta
blocking medications at the time of their injury are mixed, with
several studies suggesting preinjury beta blockade may lead toress. Las Vegas, Nevada. Feb
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ciates Ltd. Published by Elsevier Ltimproved outcomes10e12 while other studies have shown increased
mortality.13,14 More speciﬁcally, beta-blockade may improve
survival in patients with traumatic brain injury12,15 but worsen
mortality in trauma patients without brain injury.13,14 The exact
mechanisms for these differing outcomes remain uncertain.
Beta blockade has been implicated as a cause of nonresponse in
patients who fail to respond to initial trauma resuscitation.13
However, the actual heart rate response to initial trauma resusci-
tation in patients with preinjury beta blockade is not documented.
The purpose of this study was to determine the heart rate response
to trauma and trauma resuscitation in patients taking beta blockers
at the time of serious injury. We hypothesized that pre-injury beta
blockade does not impair the heart rate response to initial trauma
resuscitation.
2. Methods
This is a case-control study of patients admitted to a level I trauma center. The
Institutional Review Board approved the study protocol. Information was collected
from the level I trauma registry and from electronic and paper medical records. All
patients admitted to the hospital between January 1, 2007 and December 31, 2010
that were over 18 years of age and met criteria for activation of the trauma systemd. All rights reserved.
Table 2
Characteristics and outcomes of patients exposed and not exposed to preinjury beta
blockers.
Beta blocker
(N ¼ 70)
Non- beta
blocker
(N ¼ 310)
p-value
Age (mean) 76 54 <0.001
Injury severity score (mean) 16 16 0.281
Male (%) 40 (57.14%) 217 (70.00%) 0.038
Presence of traumatic
brain injury (%)
33 (47.14%) 92 (29.68%) 0.005
Survival (%) 47 (67.14%) 257 (82.90%) 0.003
Coronary artery disease or
peripheral vascular disease (%)
53 (75.71%) 88 (28.39%) <0.001
Diabetes (%) 19 (27.14%) 23 (7.42%) <0.001
Pulmonary disease (%) 3 (4.29%) 4 (1.29%) 0.120
Cancer (%) 2 (2.86%) 1 (0.32%) 0.089
Renal failure (%) 0 2 (0.65%) 1.000
Smoker (%) 1 (1.43%) 50 (16.13%) <0.001
Cerebrovascular disease (%) 1 (1.43%) 3 (0.97%) 0.559
On anticoagulation (%) 9 (12.86%) 14 (4.52%) 0.008
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dations for triage were selected. Patients who were dead on arrival or died in the
emergency department were excluded. Cases were all patients that met inclusion
criteria and died in the hospital. Control patients were randomly selected from the
pool of patients that met inclusion criteria and survived to hospital discharge. 1839
patients met selection criteria. There were 78 in hospital deaths. Two patients were
excluded for incomplete information; the remaining 76 patients were included as
the cases. Of the 1761 patients that survived to hospital discharge, 304 patients were
randomly selected as the control patients.
Information abstracted from the trauma registry included age, gender, Injury
Severity Score (ISS), Glasgow Coma Scale (GCS), presence of traumatic brain injury,
systolic blood pressure on arrival, emergency department length of stay, and
comorbidities. The list of comorbidities included coronary artery/peripheral vascular
disease, diabetes, pulmonary disease, cancer, renal failure requiring dialysis,
smoking, cerebral vascular accident, and conditions requiring anticoagulation.
Preadmission medications were identiﬁed by review of the computerized pread-
mission medication list compiled from physician and nursing admission notes and
pharmacy documentation. Initial and ﬁnal heart rate was abstracted from the paper
chart. Tachycardia was deﬁned as a heart rate greater than 100 beats per minute,
while bradycardia was deﬁned as a heart rate less than 60 beats per minute. The
resuscitation period was deﬁned as time from arrival in the emergency department
to time of transfer out of the emergency department to the operating room, trauma
intensive care unit, or surgical ﬂoor.
Unadjusted analyses were performed to compare demographic characteristics
and clinical status by survivor status (dichotomized as ‘survived’ or ‘died’). In
unadjusted analyses, Pearson chi-square and Fisher exact tests were used to assess
the categorical factors associated with survival or beta blocker status. Continuous
variables, such as age and heart rate, were assessed with the Wilcoxon rank-sum
test. Following univariate analyses, we used a multivariate logistic regression
model to calculate the probability of survival in the overall cohort as well as in
subgroups based on all covariates described above. All tests were considered
statistically signiﬁcant at a ¼ 0.05. All analyses were performed with SAS version
9.1.3 (SAS Institute, Cary, NC).
3. Results
380 patients were included in the study: 76 non-survivors and
304 survivors. Overall, non-survivors were older, had higher ISS,
more traumatic brain injury, more cardiac and vascular disease,
diabetes, and pulmonary disease. They were more likely to be on
anticoagulation, and more likely to be taking a beta blocker
(Table 1).
The percentage of patients taking a beta blocker at the time of
injury was 18.4%. Survival was lower in the beta blocker group than
in the non beta blocker group, 67.1% vs 82.9%, respectively
(p¼ 0.003). Patients in the beta blocker groupwere older, less likely
to be male gender, had more traumatic brain injury, diabetes, and
were more likely to be on anticoagulation than the non-beta
blocker group. Patients in the beta blocker group had similar ISS
and were less likely to smoke than the non-beta blocker group
(Table 2).
Overall, non-survivors and survivors had similar heart rates at
presentation (87 beats per minute (bpm) vs. 88 bpm, p ¼ 0.34) and
after resuscitation (84 bpm vs. 84 bpm, p ¼ 0.99). There was no
Table 1
Characteristics of non-survivors and survivors.
Non-survivors
(N ¼ 76)
Survivors
(N ¼ 304)
p-value
Age (mean) 71 55 <0.001
Injury severity score (mean) 23 14 <0.001
Male (%) 53 (69.74%) 204 (67.11%) 0.661
Presence of traumatic brain injury (%) 44 (57.89%) 81 (26.64%) <0.001
On beta blocker (%) 23 (30.26%) 47 (15.46%) 0.003
Coronary artery disease or
peripheral vascular disease (%)
41 (53.95%) 100 (32.89%) 0.001
Diabetes (%) 21 (27.63%) 21 (6.91%) <0.001
Pulmonary disease (%) 4 (5.26%) 3 (0.99%) 0.032
Cancer (%) 1 (1.32%) 2 (0.66%) 0.489
Renal failure (%) 1 (1.32%) 1 (0.33%) 0.360
Smoker (%) 5 (6.58%) 46 (15.13%) 0.059
Cerebrovascular disease (%) 2 (2.63%) 2 (0.66%) 0.180
On anticoagulation (%) 9 (11.84%) 14 (4.61%) 0.018difference in the incidence of tachycardia or bradycardia at
presentation between the two groups. Non-survivors and survivors
were equally likely to have an abnormal heart rate after resusci-
tation. Of the patients who presented with an abnormal heart rate,
therewas no difference in the likelihood of attaining a normal heart
rate following resuscitation between non-survivors and survivors
(58% vs 51%, respectively, p ¼ not signiﬁcant) (Table 3).
The beta blocker group had a lower mean heart rate at admis-
sion (83 bpm vs. 89 bpm p ¼ 0.007) and after resuscitation and
(80 bpm compared to 85 bpm p ¼ 0.02). There was no difference in
the mean heart rate change during resuscitation between the beta
blocker group and non-beta blocker group (3.2 vs. 4.3 respec-
tively, p ¼ 0.53). Patients in the beta blocker group had less
tachycardia at presentation (14.3% vs. 29.7%, respectively,
p ¼ 0.009) and more bradycardia at presentation (7.1% vs. 2.3%,
respectively, p ¼ 0.035). Of the patients who presented with an
abnormal heart rate, there was no difference in the likelihood of
attaining a normal heart rate following resuscitation between beta
blocked and non-beta blocked patients (46.7% vs. 53.3%, respec-
tively, p ¼ not signiﬁcant) (Table 4).
Factors associated with increased mortality in the overall pop-
ulation (Table 5) were age, ISS, and presence of traumatic brain
injury. Use of a beta blocker, presence of abnormal heart rate at
presentation, presence of abnormal heart rate after resuscitation, or
presence of abnormal heart rate in the setting of beta blocker use
were not associated with increased mortality. When a subset of
trauma patients without head injury was analyzed, there was no
difference in these ﬁndings (Table 6).Table 3
Hemodynamic parameters of survivors and non-survivors.
Non-survivors
(N ¼ 76)
Survivors
(N ¼ 304)
p-value
Heart rate at presentation (mean) 87 88 0.3424
Heart rate after resuscitation (mean) 84 84 0.9967
Change in heart rate (mean) 2.3 4.5 0.2479
Time in emergency department (mean) 224 278 0.0078
Systolic blood pressure (mean) 142 141 0.4581
Tachycardia on presentation (%) 21 (27.63%) 81 (26.64%) 0.8620
Bradycardia on presentation (%) 3 (3.95%) 9 (2.096%) 0.6600
Any abnormal HR (Tachycardia or
Bradycardia) after resuscitation
21 (27.63%) 68 (22.37%) 0.3330
Abnormal HR (Tachycardia or
Bradycardia) that normalized
after resuscitation
14 (58.33%) 46 (51.11%) NS
Table 4
Hemodynamic parameters of patients exposed and not exposed to preinjury beta
blockers.
Beta blocker
(N ¼ 70)
Non- beta
blocker
(N ¼ 310)
p-value
HR at presentation (mean) 83 89 0.0074
HR after resuscitation (mean) 80 85 0.0224
Updated: change in HR (mean) 3.2 4.3 0.5368
Time in ED (mean) 279 265 0.0465
Systolic blood pressure/SBP/(mean) 147 139 0.0679
Tachycardia on presentation (%) 10 (14.29%) 92 (29.68%) 0.0090
Bradycardia on presentation (%) 5 (7.14%) 7 (2.26%) 0.0350
Any abnormal HR (Tachycardia
or Bradycardia) after resuscitation
12 (17.14%) 77 (24.84%) 0.1700
Abnormal HR (Tachycardia or
Bradycardia) that normalized
after resuscitation
7 (46.67%) 53 (53.53%) NS
Table 6
Factors associated with mortality among patients without head injury.
Variable OR (95% CI) p-value
Age 1.07 (1.04e1.10) <0.0001
Injury severity score 1.07 (1.03e1.11) 0.0012
Tachycardia on presentation 2.20 (0.34e4.28) 0.7750
Bradycardia on presentation 2.37 (0.12e47.66) 0.5740
Abnormal HR (Tachycardia or
Bradycardia) after resuscitation
2.40 (0.81e7.12) 0.1161
On beta blocker at presentation 1.00 (0.30e3.31) 0.9991
Tachycardia on beta blocker on presentation 0 (0e) 0.9872
Bradycardia on beta blocker on presentation 0.33 (0.01e15.66) 0.5731
Coronary artery disease or
peripheral vascular disease
2.28 (0.85e6.17) 0.1032
On anticoagulation 0.9 (0.14e5.87) 0.9107
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The present study shows that trauma patients taking beta
blockers at the time of injury have a lower mean heart rate as well
as a lower incidence of tachycardia and higher incidence of
bradycardiawhen comparedwith patients not taking beta blockers.
Of those patients who presented to the hospital with an abnormal
heart rate, the likelihood of attaining a normal heart rate after
resuscitation was nearly identical between patients on a beta
blocker and those not on a beta blocker. While patients who died
after being admitted to the hospital were more likely to be taking
a beta blocker than those who survived, being on a beta blocker at
presentation was not independently associated with mortality.
The volume of trauma involving elderly patients is increasing
steadily with time.17 Thus, it can be inferred that the number of
trauma patients taking beta blockers is also increasing. In the
existing literature, the effect of preinjury beta blockade on outcome
in trauma patients remains uncertain.
Multiple studies have shown a potential survival advantage in
trauma patients taking beta blockers. Arbabi et al. showed beta
blockade to be associated with signiﬁcantly lower the risk of death
in a cohort of 4117 trauma patients.10 The reduced risk was most
prominent among patients with head injury. Likewise, Cotton and
Inaba, in studies of 420 and 1156 patients respectively, showed beta
blocker exposure to be associated with signiﬁcantly reduced
mortality in patients with traumatic brain injury.12,15 Proposed
mechanisms of improved outcome with beta blockade include
decreased tachycardia and myocardial oxygen demand,18 as well as
improved oxygen utilization.19 Beta blockers have been shown to
decrease circulating levels of the pro-inﬂammatory cytokine
interleukin-6 after injury in patients at risk for heart disease.11 The
same study showed preinjury beta blockade to be associated with
a less severe initial base deﬁcit.11Table 5
Factors associated with mortality in the overall study population.
Variable OR (95% CI) p-value
Age 1.04 (1.02e1.06) <0.0001
Injury severity score 1.08 (1.02e1.06) <0.0001
Traumatic brain injury 2.21 (1.20e4.05) 0.0104
On beta blocker at presentation 0.90 (0.40e2.03) 0.7981
Tachycardia on presentation 1.07 (0.49e2.34) 0.8720
Bradycardia on presentation 0.75 (0.12e4.76) 0.7627
Tachycardia on beta blocker at presentation 3.54 (0.60e20.74) 0.1617
Bradycardia on beta-blocker at presentation 0.85 (0.04e17.62) 0.9178
Abnormal HR after resuscitation 1.46 (0.69e3.09) 0.3186
Coronary artery disease or
peripheral vascular disease
1.13 (0.59e2.17) 0.7213
On anticoagulation 1.54 (0.56e4.26) 0.4059Other large studies associate preinjury beta blockade with
higher mortality. In a study of 1479 elderly trauma patients, beta
blocker use was associated with elevated mortality in patients
without head injury.14 Likewise, in a large study of 5971 trauma
patients with preexisting cardiac disease, Ferraris et al. showed
beta blocker use to be associatedwith a relative risk of death of 2.06
(1.33e3.18).13 It has been suggested that by blunting the stress
response to shock, beta blockade may render trauma victims
incapable of increasing cardiac output appropriately to maintain
tissue perfusion.14 Ferraris et al. suggest that failure of a patient to
respond to normal resuscitation may be due to beta blockade, and
that pressor agents such as beta-adrenergic agonists may be
required to augment cardiac output in such patients.13
Toourknowledge, thepresentstudy is theonlystudy investigating
the effect of beta-blockade on heart rate during initial trauma resus-
citation. While we did observe a lower mean heart rate, lower inci-
dence of tachycardia and higher incidence of bradycardia, the heart
rate response to resuscitationwas similar inpatients exposed andnot
exposed to beta blocker. Thus, an abnormal response to resuscitation
in a patient on a beta blocker may be due to other factors, and use of
beta-adrenergic agonists may not be beneﬁcial. Again, while dece-
dentsweremore likely to be exposed to a beta blocker than survivors,
betablockerusewasnot independentlyassociatedwithmortality. It is
possible thatbetablockeruse isamarkerofpreexisting illness andnot
a direct contributor to worsened outcome.
The present study has several limitations. First, we chose to
perform a case-control study, and the size of the study population
was limited by a relatively small number of in-hospital deaths. It is
possible that a larger sample size might have revealed a small effect
of beta blockade on mortality. Second, we used pulse recorded at
presentation and pulse recorded before leaving the emergency
department as a reﬂection of response to resuscitation. It is possible
that additional periods of tachycardia and bradycardia occurred in
the interim between presentation and discharge from the ED. Third,
some patients in the study who sustained more severe injuries
were likely taken for emergency surgery before a period of
adequate resuscitation, while others may have experienced delays
not related to management. It is thus possible that the vital signs
recorded in the ED do not speciﬁcally represent the period of
resuscitation. Finally, the exact measures, such as volume of crys-
talloid and colloid, received during the period of resuscitation in
the emergency department were not investigated. More controlled
studies examining the effects of beta blockade on response to acute
resuscitation in trauma are needed. Further efforts should focus on
the effects of beta blockade on other physiologic parameters and
markers of end organ perfusion during acute trauma resuscitation,
including blood pressure, pH, base deﬁcit and urine output.
While preinjury beta blocker use is associated with lower pre-
senting heart rate, more bradycardia, and less tachycardia, there is
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Beta blocker use was not independently associated with mortality
in this study. Based on these data a failure to respond to initial
trauma resuscitation should not be presumed to be the result of
preinjury beta blockade and should prompt further investigation
into the cause of hemodynamic instability.
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